Patients and health insurance providers could save at least $71 billion over 10 years if there were a regulatory mechanism that allowed for the marketing of generic biotech medicines, according to a new study. Currently there is no legal pathway …
A less confident physician might have been humbled by the letters Dr. Mike Kelly received last year from two insurers. Regence BlueShield and UnitedHealthcare informed Kelly that he failed to qualify for their respective designations as a high-quality doctor. Health …
People with employer-sponsored health coverage choose to enroll in traditional plans over consumer directed products, which have been touted as a way to lower health care costs, according to a survey released Friday. The study also found that 39 percent …
Health insurers spend less on patients with individual policies than those with employer-sponsored plans, according to a new study released Friday. Patients with individual policies also have higher out-of-pocket expenses than their counterparts who purchase plans through their employers, the …
Merck & Co.’s board of directors said last week that a 20-month investigation funded by the pharmaceutical company found that senior management acted responsibly in developing and marketing its now withdrawn pain reliever Vioxx. The 1,700-page report, which cost $21 …
If the plaintiffs in the Vioxx case currently being tried in New Jersey win, the damage awards against Merck & Co. are likely to be modest and not affect the drugmaker’s ability to manage the financial fallout from the thousands …
